UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.22 Million Stock Holdings in Pharvaris (NASDAQ:PHVS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Pharvaris (NASDAQ:PHVS - Free Report) by 30.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 63,734 shares of the company's stock after acquiring an additional 14,838 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.12% of Pharvaris worth $1,222,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of PHVS. Palumbo Wealth Management LLC bought a new position in shares of Pharvaris during the fourth quarter worth about $196,000. KLP Kapitalforvaltning AS bought a new position in shares of Pharvaris during the fourth quarter worth about $111,000. JPMorgan Chase & Co. lifted its holdings in Pharvaris by 1,125.3% in the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after purchasing an additional 2,847 shares during the period. Geode Capital Management LLC grew its position in Pharvaris by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock valued at $735,000 after buying an additional 1,356 shares in the last quarter. Finally, FMR LLC grew its position in Pharvaris by 3.6% in the 4th quarter. FMR LLC now owns 5,395,370 shares of the company's stock valued at $103,429,000 after buying an additional 189,714 shares in the last quarter.

Analyst Ratings Changes

PHVS has been the subject of a number of recent analyst reports. Cantor Fitzgerald decreased their target price on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. Guggenheim started coverage on shares of Pharvaris in a research report on Wednesday. They set a "buy" rating and a $32.00 price objective for the company. Finally, Wedbush restated an "outperform" rating and set a $27.00 price objective on shares of Pharvaris in a research report on Thursday, June 5th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $36.20.

Pharvaris Stock Performance

Shares of NASDAQ PHVS traded down $0.53 during mid-day trading on Friday, reaching $16.70. The company had a trading volume of 12,409 shares, compared to its average volume of 74,223. The stock has a fifty day moving average of $15.83 and a two-hundred day moving average of $16.95. The company has a market capitalization of $873.24 million, a price-to-earnings ratio of -5.96 and a beta of -2.86. Pharvaris has a 12-month low of $11.51 and a 12-month high of $25.50.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.09). Sell-side analysts forecast that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.